^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
JS111
i
Other names: JS111, APL1898, AP-L1898
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shanghai Junshi Biosci, Suzhou Junjing Biomed
Drug class:
EGFR inhibitor
Related drugs:
7ms
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations (clinicaltrials.gov)
P1/2, N=42, Recruiting, Suzhou Junjing BioSciences Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
JS111
7ms
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations (clinicaltrials.gov)
P1/2, N=42, Not yet recruiting, Suzhou Junjing BioSciences Co., Ltd.
New P1/2 trial
|
JS111
over4years
AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=156, Recruiting, Suzhou Junjing BioSciences Co., Ltd.
Clinical • New P1/2 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
JS111
Share via
